AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03655444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
Study NCT03655444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is commercially available
Study NCT03655444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Phase II patients only~* If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab.
Study NCT03655444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: * Phase II patients only~* Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression.
Study NCT03655444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-30
Description: * Phase II patients only~* Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)
Study NCT03996772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral Tablet
Description: Factor Xa Inhibitor
Study NCT03996772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Direct Thrombin Inhibitor
Study NCT03996772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban Tablets
Description: Factor Xa Inhibitor
Study NCT03996772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Factor Xa Inhibitor
Study NCT03619629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio-tape
Description: Kinesiotape will be applied both ankles as Correction technique.
Study NCT03619629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement
Description: 'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
Study NCT03619629 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio-taping
Description: Sham Kinesio-taping technique will be applied both ankles.
Study NCT03619629 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Mulligan's mobilization with movement
Description: Sham Mulligan's mobilization with movement technique will be applied both ankles.
Study NCT02420444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
Study NCT02420444 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BCG SSI
Description: The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
Study NCT02420444 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
Study NCT02420444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
Study NCT02420444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
Study NCT03401918 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine ERA and microbiome testing
Description: Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
Study NCT03401918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotics and vaginal probiotics
Description: For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
Study NCT00672659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram + Pipamperone
Description: Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
Study NCT02158663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS Device
Study NCT01286090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisapride
Description: One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
Study NCT01286090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet taken orally 4 times a day for up to 8 weeks.
Study NCT03892863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active repetitive transcranial magnetic stimulation
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
Study NCT03892863 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
Study NCT00672659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
Study NCT04193696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
Description: The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
Study NCT02600403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
Study NCT02600403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual evoked potential (VEP)
Description: Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
Study NCT03251131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management
Description: Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
Study NCT00472758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI 545
Description: IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
Study NCT02600403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Visual Field (HVF)
Description: Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
Study NCT00749177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healing options
Description: Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
Study NCT01565876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minkal- Auxiliary device to alleviate backload
Description: The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards.
Study NCT03838276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AL 150 BPL100
Description: Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
Study NCT03838276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AL 100 BPL 150
Description: Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
Study NCT02363803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
Study NCT00472758 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
Study NCT02415842 — intervention group
Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
Study NCT02363803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
Study NCT02363803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline, approved for hypovolemia, and homeostasis.
Study NCT02363803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, approved for hypovolemia, and homeostasis.
Study NCT02105779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
Study NCT02105779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Cognitive Training
Description: We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
Study NCT00448903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin sodium
Study NCT00448903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0,9%
Study NCT01665209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study NCT01665209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study NCT03249662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 200 mg
Description: bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
Study NCT03249662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg
Description: bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
Study NCT03224559 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Electrical Stimulation
Description: Transcranial Electrical Stimulation
Study NCT03740893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.
Study NCT03740893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.
Study NCT03740893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.
Study NCT01604993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach soup
Description: 556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
Study NCT01604993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Asparagus soup
Description: 556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
Study NCT03729271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be given during weeks 2-4
Study NCT03729271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose and lactulose hydrogen breath testing
Description: Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
Study NCT04097587 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: experimental group
Description: This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
Study NCT04097587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
Study NCT03495583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early introduction
Description: Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
Study NCT01004276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New, improved smoking cessation management module
Description: The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
Study NCT02730143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Altitude exposure
Study NCT03860558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
Study NCT03860558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participants will not undergo an intervention.
Study NCT03189056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chagas serology
Description: IFI + ELISA method if no biological confirmation of chagas disease is in our possession
Study NCT03189056 — intervention group
Intervention type: BIOLOGICAL
Intervention: Creatinina
Description: Plasmatic single mesure after consultation 1, to evaluate renal function
Study NCT03189056 — intervention group
Intervention type: PROCEDURE
Intervention: Urodynamic exploration
Description: With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
Study NCT00164697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting group
Description: Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
Study NCT02437227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCT3833
Description: CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
Study NCT04120103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doll therapy
Description: The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
Study NCT04120103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
Study NCT04385329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points
Description: Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
Study NCT04385329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave therapy on plantar fascia only
Description: Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
Study NCT03069521 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EndoArt® Artificial Endothelial Layer
Description: device is intended for use as an endothelial kearatoprosthesis